Jazz Pharma: Short Book Flips as Options Turn Defensive

Jazz Pharmaceuticals reports Q3 results on November 4 with a notable reversal from the positioning that preceded yesterday's earlier earnings date: options traders have swung sharply toward protection, while short interest remains elevated at 9.2% of the free float.

The clearest change since the prior preview is in options. The put/call ratio jumped to 0.89 on November 2, more than double the 20-day average of 0.42 and running 2.4 standard deviations above it. That compares to readings of 0.19 to 0.20 across most of last week, when calls dominated. The stock closed at $214.44, up 4.2% over the past week but down 9% over the past month, outperforming the median weekly gain of roughly 2.2% among its closest peers. Borrow conditions remain loose: availability is ample at 684% of shares already borrowed, meaning roughly seven shares remain available for every one lent out, with cost to borrow a low 0.48%.

The short position itself is meaningful but not escalating fast. At 9.2% of the free float, short interest has grown 16% over the past month, though it edged down 2% over the past week. The month-long build coincided with a falling share price, a pattern that can reflect either genuine conviction or mechanical hedging. The ORTEX short score has drifted lower from 57.7 in mid-October to 54.8 now, suggesting the short-side pressure is easing slightly rather than intensifying.

Analyst opinion has been broadly constructive, though the direction of recent revisions is mixed. JP Morgan raised its target to $300 from $276 on October 28, maintaining its Overweight rating. Morgan Stanley trimmed its target slightly to $314 from $322 the prior week while staying positive. The consensus mean target of $295 sits roughly 38% above the current price. The bull case centres on the Ziihera opportunity in HER2+ gastric cancer, where management recently raised peak revenue guidance to $3-5 billion, alongside a maturing neuroscience franchise built on Xywav and Epidiolex. Bears point to pipeline binary risk in Zepzelca's first-line SCLC trial, potential generic pressure on Epidiolex from 2027, and the risk that Rylaze and Epidiolex grow more slowly than consensus expects.

Medicaid reimbursement data from the Centers for Medicare & Medicaid Services adds one grounding data point. Medicaid dollars reimbursed for Jazz drugs have risen for four consecutive quarters and were up 11% year on year in Q1 2026, reaching $219 million for the quarter. There are no measured datasets that have been shown to lead Jazz's reported financials, so the Medicaid trend is context rather than a forward signal.

The print will test whether Ziihera's commercial ramp can justify the valuation premium implied by the Street's targets, and whether the neuroscience portfolio has stabilised after two consecutive quarters of softer-than-expected results.